Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis

Desmet, 1994, Classification of chronic hepatitis: diagnosis, grading and staging, Hepatology, 19, 1513, 10.1002/hep.1840190629

Soloway, 1972, Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis, Gastroenterology, 63, 820, 10.1016/S0016-5085(19)33223-8

Murray-Lyon, 1973, Controlled trial of prednisone and azathioprine in active chronic hepatitis, Lancet, 1, 735, 10.1016/S0140-6736(73)92125-9

Kirk, 1980, Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis, Gut, 21, 78, 10.1136/gut.21.1.78

Czaja, 2010, Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis, Gastroenterology, 139, 58, 10.1053/j.gastro.2010.04.053

Manns, 2010, Diagnosis and management of autoimmune hepatitis, Hepatology, 51, 2193, 10.1002/hep.23584

Manns, 2001, Autoimmune hepatitis: clinical challenges, Gastroenterology, 120, 1502, 10.1053/gast.2001.24227

Richardson, 2000, Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine, J Hepatol, 33, 371, 10.1016/S0168-8278(00)80271-8

Hennes, 2008, Mycophenolate mofetil as second line therapy in autoimmune hepatitis?, Am J Gastroenterol, 103, 3063, 10.1111/j.1572-0241.2008.02180.x

Fernandez, 1999, Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis, Am J Gastroenterol, 94, 241, 10.1111/j.1572-0241.1999.00807.x

Van Thiel, 1995, Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial, Am J Gastroenterol, 90, 771

Thalen, 1979, Synthesis and anti-inflammatory properties of budesonide, a new non-halogenated glucocorticoid with high local activity, Arzneimittelforschung, 29, 1687

Danielson, 1994, Oral budesonide for treatment of autoimmune chronic hepatitis, Aliment Pharmacol Ther, 8, 585, 10.1111/j.1365-2036.1994.tb00334.x

Czaja, 2000, Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis, Gastroenterology, 119, 1312, 10.1053/gast.2000.0010000001

Wiegand, 2005, Budesonide in previously untreated autoimmune hepatitis, Liver Int, 25, 927, 10.1111/j.1478-3231.2005.01122.x

Alvarez, 1999, International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis, J Hepatol, 31, 929, 10.1016/S0168-8278(99)80297-9

Knodell, 1981, Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis, Hepatology, 1, 431, 10.1002/hep.1840010511

O'Brien, 1979, A multiple testing procedure for clinical trials, Biometrics, 35, 549, 10.2307/2530245

Lehmacher, 1999, Adaptive sample size calculations in group sequential trials, Biometrics, 55, 1286, 10.1111/j.0006-341X.1999.01286.x

Czaja, 2009, Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients, Semin Liver Dis, 29, 315, 10.1055/s-0029-1233530

Czaja, 1993, Significance of HLA DR4 in type 1 autoimmune hepatitis, Gastroenterology, 105, 1502, 10.1016/0016-5085(93)90157-8

Krawitt, 2006, Autoimmune hepatitis, N Engl J Med, 354, 54, 10.1056/NEJMra050408

Czaja, 1995, The validity and importance of subtypes in autoimmune hepatitis: a point of view, Am J Gastroenterol, 90, 1206

Manns, 1987, Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen, Lancet, 1, 292, 10.1016/S0140-6736(87)92024-1

Kanzler, 1999, Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis, J Hepatol, 31, 635, 10.1016/S0168-8278(99)80342-0